Pharmaspectra achieves unprecedented growth in 2021, with 27 new clients and reveals plans to expand presence in the US and Europe

Pharmaspectra, the world leader in scientific data, expert mapping and Share of Scientific VoiceTM measurement for pharmaceutical Medical Affairs teams, announced that 2021 has been its most successful year since the company’s inception in 2004.

During a period of transformation for the pharmaceutical industry, Pharmaspectra has worked closely with Medical Affairs teams, helping them adapt and optimize the way they engage with experts. By applying its uniquely large data set, curated expert identification, and powerful, strategic analytics, clients have been able to significantly improve their ability to plan, execute decisions, and create impact.

In 2021, Pharmaspectra has:

  • Achieved a year-to-date revenue growth of 30%, driven by existing account expansion and new client engagements 
  • Added 27 new clients, across pharma, medical devices and small biotech
  • Enjoyed their largest-ever sales month in October
  • Launched a faster, smarter and more intuitive KOL platform, Pharmaspectra Experts  

These important milestones follow an 18-month period of significant investment by Pharmaspectra in its technology platforms, client services and data science teams. 

“Our unprecedented growth in 2021 is thanks to our talented team’s dedication and close collaboration with our clients” said Pharmaspectra CEO, Jez Moulding. “From our scientific data experts, medical strategists and client services team, to improving the user experience with our new Experts platform, we’ve continued to strengthen our solutions and customer support, enabling better-use of our data and analytics.”

“The engagement on our data and platforms is at an all-time high. To build on this growth, we’re now recruiting for a number of business development and client services positions across the US and Europe for 2022. We’re also reviewing our acquisition opportunities to complement our data, mapping, and measurement capabilities.”, adds Jez Moulding.